Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819950 | 0.87 | L3MBTL1 (0.35) | THRBL3MBTL1 | |
| SCHEMBL1128473 | 0.81 | — | — | |
| SCHEMBL5015809 | 0.80 | THRB (0.33) | THRB | |
| SCHEMBL56282 | 0.80 | THRB (0.33) | THRB | |
| SCHEMBL13434035 | 0.80 | GAA (0.42) | THRB | |
| SCHEMBL291088 | 0.80 | ALDH1A1 (0.33) | THRB | |
| SCHEMBL16823234 | 0.78 | THRB (0.32) | THRB | |
| SCHEMBL80733 | 0.78 | LMNA (0.35) | THRB | |
| SCHEMBL20109904 | 0.78 | ELANE (0.32) | THRB | |
| SCHEMBL13201625 | 0.76 | THRB (0.30) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| US-6399590-B2 | REPERFUSION INJURY; 2-DEOXY-6-O-(2-DEOXY-4-O-PHOSPHONO-3-O-(3-TETRADECANOYLOXYTETRADECANOYL) -2-(3-OCTADECANOYLOXY-TETRADECANOYLAMINO)-BETA-D-GLUCOPYRANOSYL)-2-(3 -HEXADECANOYLOXYTETRADECANOYLAMINO)-D-GLUCOPYRANOSE | CORIXA CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | CORIXA CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| US-6013640-A | ANTIISCHEMIC AGENTS | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | THRB 2976/4885L3MBTL1 3352/4885 |
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | THRB 4578/4885L3MBTL1 4215/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | THRB 1052/4885L3MBTL1 1425/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | THRB 4496/4885L3MBTL1 1938/4885 |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | THRB 2791/4885L3MBTL1 3770/4885 |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | PYGL, GPI, PNLIP | THRB 3560/4885L3MBTL1 635/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | THRB 3416/4885L3MBTL1 3084/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | THRB 4141/4885L3MBTL1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.